Efficacy and Safety of Lesinurad (RDEA594), A Novel Uricosuric Agent, Given In Combination with Allopurinol in Allopurinol-Refractory Gout Patients: Preliminary Results from the Randomized, Double-Blind, Placebo-Controlled, Phase 2B Extension Study.

Sundy, John; Perez-Ruiz, Fernando; Krishnan, Eswar; Hingorani, Vijay; Welp, Jody; Suster, Matt; Manhard, Kimberly; Cravets, Matt; Hagerty, David; Quart, Barry

Efficacy and Safety of Lesinurad (RDEA594), A Novel Uricosuric Agent, Given In Combination with Allopurinol in Allopurinol-Refractory Gout Patients: Preliminary Results from the Randomized, Double-Blind, Placebo-Controlled, Phase 2B Extension Study.

Sundy, John
Perez-Ruiz, Fernando
Krishnan, Eswar
Hingorani, Vijay
Welp, Jody
Suster, Matt
Manhard, Kimberly
Cravets, Matt
Hagerty, David
Quart, Barry

Zeitschrift:

ARTHRITIS AND RHEUMATISM

ISSN: 0004-3591, 1529-0131

Datum der Publikation: 2011

Ausgabe: 63

Nummer: 10

Kongress: 75th Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) / 46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP)

Art: Konferenz-Beitrag

GOOGLE SCHOLAR

Fuente de los datos: WoS